Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Oct 1;106(10):2774-2778.
doi: 10.3324/haematol.2021.278654.

Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study

Paolo Strati  1 , Sven De Vos  2 , Jia Ruan  3 , Kami J Maddocks  4 , Christopher R Flowers  5 , Simon Rule  6 , Priti Patel  7 , Yan Xu  7 , Helen Wei  7 , Melanie M Frigault  7 , Roser Calvo  8 , Martin J S Dyer  9
Affiliations
Clinical Trial

Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study

Paolo Strati et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Patient-level responses. (A) Best response and maximum change in tumor burden by patient. (B) Duration of treatment with best response by patient. Arrow in panel (B) indicates the patient is continuing treatment with acalabrutinib. aBest response for one patient was unknown and thus not included in this graph. CR: complete response; ORR: overall response rate; PD: progressive disease; PR: partial response; Ref: refractory; Rel: relapsed; SD: stable disease.
Figure 2.
Figure 2.
Cell of origin by NanoString. (A) Responders including duration of response. (B) Best overall response in the 15 patients who had evaluable samples available for NanoString subtyping. All enrolled patients (n=21) had local non–germinal center B-cell (GCB) immunohistochemistry cell-of-origin testing. Archival tumor samples were submitted for central gene sequencing analysis (n=15) using the Lymphoma Subtyping Test (LST) by NanoString platform (Covance Genomics Labs). aCensored. ASCT: autologous stem cell transplantation; BEAM: BiCNU (carmustine), etoposide, Ara-C (cytarabine), and melphalan; CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisolone; CR: complete response; GCB: germinal center B-cell; HSCT: hematopoietic stem cell transplantation; LPS: linear predictor score; PD: progressive disease; PFS: progression-free survival; PR: partial response; R: rituximab; R/R: relapsed/refractory; R-CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisolone + rituximab; R-ESHAP: rituximab, etoposide, solu-medrone, high-dose cytarabine, and cisplatin; RGDB: cisplatin, dexamethasone, gemcitabine and rituximab; RICE: rituximab, ifosfamide, carboplatin, and etoposide; SD: stable disease.
See this image and copyright information in PMC

References

    1. Swerdlow SH, Campo E, Pileri SA, et al. . The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390. - PMC - PubMed
    1. Alizadeh AA, Eisen MB, Davis RE, et al. . Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-511. - PubMed
    1. Davis RE, Ngo VN, Lenz G, et al. . Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88-92. - PMC - PubMed
    1. Wilson WH, Young RM, Schmitz R, et al. . Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922-926. - PMC - PubMed
    1. Walter HS, Rule SA, Dyer MJ, et al. . A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. 2016;127(4):411-419. - PMC - PubMed

Publication types

MeSH terms